Key result
Female ACS patients undergoing PCI have less optimal medical therapy and more pseudoaneurysms despite similar MACCE.
Why the study?
Prior studies demonstrated gender disparity in treatment and outcomes of patients undergoing PCI for ACS, but contemporary evidence is needed to assess if this persists.
Are there gender disparities in treatment and outcomes among patients undergoing PCI for ACS?
Observational (n=468)
No
Are there gender disparities in treatment and outcomes among patients undergoing PCI for ACS?
Absolute Event Rate: 2.9% vs 3.9%
p-value: p=0.8
Despite similar 30-day MACCE, women undergoing PCI for ACS receive less optimal medical therapy and experience more femoral access site complications than men.
May signal disparities in ACS PCI care for women; hypothesis-generating and should not yet change practice.
INTRODUCTION: Prior studies have demonstrated evidence of a disparity in the treatment and outcome of male compared to female patients undergoing percutaneous coronary intervention (PCI). MATERIALS AND METHODS: From a dedicated database, we retrospectively analysed all consecutive patients with acute coronary syndrome (ACS) admitted to our institution for PCI in 2008. Baseline and procedural characteristics as well as complications were then evaluated for male patients (n = 331) as compared with female patients (n = 137). RESULTS: Women were noted to be older at the time of presentation (66.1 +/- 10.0 vs 60.7 +/- 11.6 years, P <0.00001), the groups were otherwise well matched in terms of baseline characteristics. Female patients were treated with significantly smaller diameter stents (2.86 +/- 0.44 vs 2.96 +/- 0.50 mm, P = 0.04), though the proportion of drug-eluting stents was similar (53.7% vs 50.5%, P = 0.5). Female patients were significantly less likely to receive optimal medical therapy with lesser use of glycoprotein IIb/IIIa inhibitor (26.3% vs 55.3%, P <0.0000001), and beta-blockers (83.9% vs 90.9%, P = 0.04). At 30 days, there were no differences in the rate of major adverse cerebrovascular or cardiac events (2.9% vs 3.9%, P = 0.8), though females had a significantly higher rate of femoral access site pseudoaneurysm (4.4% vs 0.9%, P = 0.02). CONCLUSIONS: There remains evidence for continued gender disparity in contemporary practice; despite evidence for efficacy in ACS patients, females received a notably lower use of glycoprotein IIb/IIIa inhibitors and beta-blockers. Women are also significantly more likely to develop femoral access site complications with pseudoaneurysm development; it is important therefore to optimise procedures for sheath removal in female patients or give strong consideration to the use of radial access site.
No takes yet. Share an insight, caveat, or question.
Jibran et al. (2010) conducted an observational in Acute coronary syndrome (n=468). Female gender vs. Male gender was evaluated on Major adverse cerebrovascular and cardiac events (MACCE) at 30 days (p=0.8). Female patients undergoing PCI for acute coronary syndrome received significantly less optimal medical therapy and had higher rates of femoral access site pseudoaneurysms compared to men, despite similar 30-day rates of major adverse cardiovascular events.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: